Annual Accounts Receivable
$1.46 M
-$1.79 M-55.16%
December 31, 2023
Summary
- As of February 8, 2025, LVTX annual accounts receivable is $1.46 million, with the most recent change of -$1.79 million (-55.16%) on December 31, 2023.
- During the last 3 years, LVTX annual accounts receivable has risen by +$319.00 thousand (+27.98%).
- LVTX annual accounts receivable is now -55.16% below its all-time high of $3.25 million, reached on December 31, 2022.
Performance
LVTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$536.00 K
-$46.00 K-7.90%
September 30, 2024
Summary
- As of February 8, 2025, LVTX quarterly accounts receivable is $536.00 thousand, with the most recent change of -$46.00 thousand (-7.90%) on September 30, 2024.
- Over the past year, LVTX quarterly accounts receivable has dropped by -$541.00 thousand (-50.23%).
- LVTX quarterly accounts receivable is now -98.94% below its all-time high of $50.59 million, reached on September 30, 2022.
Performance
LVTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
LVTX Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -55.2% | -50.2% |
| 3 y3 years | +28.0% | -50.2% |
| 5 y5 years | +2014.5% | -50.2% |
LVTX Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -55.2% | +301.9% | -98.9% | +47.7% |
| 5 y | 5-year | -55.2% | +2014.5% | -98.9% | +47.7% |
| alltime | all time | -55.2% | +2014.5% | -98.9% | +47.7% |
LAVA Therapeutics NV Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $536.00 K(-7.9%) |
| Jun 2024 | - | $582.00 K(-21.0%) |
| Mar 2024 | - | $737.00 K(-49.5%) |
| Dec 2023 | $1.46 M(-55.2%) | $1.46 M(+35.5%) |
| Sep 2023 | - | $1.08 M(-73.0%) |
| Jun 2023 | - | $3.99 M(+97.7%) |
| Mar 2023 | - | $2.02 M(-37.9%) |
| Dec 2022 | $3.25 M | $3.25 M(-93.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $50.59 M(+9536.2%) |
| Jun 2022 | - | $525.00 K(+24.7%) |
| Mar 2022 | - | $421.00 K(+16.0%) |
| Dec 2021 | $363.00 K(-68.2%) | $363.00 K(-74.1%) |
| Sep 2021 | - | $1.40 M(+227.3%) |
| Jun 2021 | - | $428.40 K(-3.1%) |
| Mar 2021 | - | $442.00 K(-61.2%) |
| Dec 2020 | $1.14 M(+1552.2%) | $1.14 M |
| Dec 2019 | $69.00 K | - |
FAQ
- What is LAVA Therapeutics NV annual accounts receivable?
- What is the all time high annual accounts receivable for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV annual accounts receivable year-on-year change?
- What is LAVA Therapeutics NV quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for LAVA Therapeutics NV?
- What is LAVA Therapeutics NV quarterly accounts receivable year-on-year change?
What is LAVA Therapeutics NV annual accounts receivable?
The current annual accounts receivable of LVTX is $1.46 M
What is the all time high annual accounts receivable for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high annual accounts receivable is $3.25 M
What is LAVA Therapeutics NV annual accounts receivable year-on-year change?
Over the past year, LVTX annual accounts receivable has changed by -$1.79 M (-55.16%)
What is LAVA Therapeutics NV quarterly accounts receivable?
The current quarterly accounts receivable of LVTX is $536.00 K
What is the all time high quarterly accounts receivable for LAVA Therapeutics NV?
LAVA Therapeutics NV all-time high quarterly accounts receivable is $50.59 M
What is LAVA Therapeutics NV quarterly accounts receivable year-on-year change?
Over the past year, LVTX quarterly accounts receivable has changed by -$541.00 K (-50.23%)